Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules

Abstract

The present application discloses compositions and methods of synthesis and use of 18 F or 19 F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the 18 F or 19 F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the 18 F or 19 F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the labeled molecule may be used for imaging in a subject without purification after labeling.

What is claimed is:  
     
       1. A composition comprising an  19 F- or  18 F-labeled targeting molecule comprising a bifunctional chelating agent of the structure 
       
         
           
           
               
               
           
         
         wherein R 1  and R 2  are independently selected from the group consisting of
 —CH 2 —COOH 
 —CH 2 —CH 2 —OH 
 —CH(CH 3 )—COOH 
 —CH(C 6 H 5 )—COOH 
 
       
       
         
           
           
               
               
           
         
         and R 3  is selected from the group consisting of: 
       
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         wherein M selected from the group consisting of aluminum, gallium, indium, lutetium and thallium and X is  19 F or l8 F, wherein n =1-9 and wherein R═F, CH 2 F, CHF 2 , CH 3  or OCF 3 . 
       
     
     
       2. The composition of  claim 1 , wherein the targeting molecule is selected from the group consisting of a protein, a peptide, an antibody, a monoclonal antibody, a bispecific antibody, a multispecific antibody, an antibody fusion protein, an antigen-binding antibody fragment, an affibody and a targetable construct. 
     
     
       3. The composition of  claim 2 , wherein the antibody is selected from the group consisting of hR1 (anti-IGF-1R), hPAM4 (anti-pancreatic cancer mucin), hA20 (anti-CD20), hA19 (anti-CD 19), hIMMU31 (anti-AFP), hLL1 (anti-CD74), hLL2 (anti-CD22), hMu-9 (anti-CSAp), hL243 (anti-HLA-DR), hMN-14 (anti-CEACAM5), hMN-15 (anti-CEACAM6), hRS7 (anti-EGP-1) and hMN-3 (anti-CEACAM6). 
     
     
       4. The composition of  claim 2 , wherein the antibody is selected from the group consisting of Ab 124 (anti-CXCR4), Ab125 (anti-CXCR4), abciximab (anti -glycoprotein IIb/IIIa), alemtuzumab (anti-CD52), bevacizumab (anti-VEGF), cetuximab (anti-EGFR), gemtuzumab (anti-CD33), ibritumomab (anti-CD20), panitumumab (anti-EGFR), rituximab (anti-CD20), tositumomab (anti-CD20), trastuzumab (anti-ErbB2), abagovomab (anti-CA-125), adecatumumab (anti-EpCAM), atlizumab (anti-IL-6 receptor), benralizumab (anti-CD125), CC49 (anti-TAG-72), AB-PG1-XG1-026 (anti-PSMA), D2/B (anti-PSMA), tocilizumab (anti-IL-6 receptor), basiliximab (anti-CD25), daclizumab (anti-CD25), efalizumab (anti-CD11a), GA101 (anti-CD20), muromonab-CD3 (anti-CD3 receptor), natalizumab (anti-α4 integrin), omalizumab (anti-IgE), infliximab (anti-TNF-α), certolizumab pegol (anti-TNF-α), adalimumab (anti-TNF-α), and belimumab (anti-BLyS). 
     
     
       5. The composition of  claim 2 , wherein the antibody fragment is selected from the group consisting of F(ab′) 2 , Fab′, F(ab) 2 , Fab, scFv and VHH (single domain antibody). 
     
     
       6. The composition of  claim 1 , wherein the targeting molecule binds to a tumor-associated antigen (TAA). 
     
     
       7. The composition of  claim 5 , wherein the TAA is selected from the group consisting of carbonic anhydrase IX, CCL19, CCL21, CSAp, CD1, CD1a, CD2, CD3, CD4, CD5, CD8, CD11A, CD14, CD15, CD16, CD18, CD19, IGF-1R, CD20, CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40, CD40L, CD45, CD46, CD52, CD54, CD55, CD59, CD64, CD66a-e, CD67, CD70, CD74, CD79a, CD80, CD83, CD95, CD126, CD133, CD138, CD147, CD154, CXCR4, CXCR7, CXCL12, HIF-1-α, AFP, PSMA, CEACAM5, CEACAM-6, c-met, B7, ED-B of fibronectin, Factor H, FHL-1, Flt-3, folate receptor, GROB, HMGB-1, hypoxia inducible factor (HIF), insulin-like growth factor-1 (ILGF-1), IFN- 65  , IFN-α, IFN-β, IL-2, IL-4R, IL-6R, IL-13R, IL-15R, IL-17R, IL-18R, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, IL-25, IP-10, MAGE, mCRP, MCP-1, MIP-1A, MIP-1B, MIF, MUC1, MUC2, MUC3, MUC4, MUC5, NCA-95, NCA-90, Ia, EGP-1, EGP-2, HLA-DR, tenascin, Le(y), RANTES, T101, TAC, Tn antigen, Thomson-Friedenreich antigens, tumor necrosis antigens, TNF-α, TRAIL receptor (R1 and R2), VEGFR, EGFR, P1GF, complement factors C3, C3a, C3b, C5a, and C5. 
     
     
       8. The composition of  claim 1 , wherein the targeting molecule is somatostatin, epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), bombesin, methotrexate, growth hormone, RGD (arginine-glycine-aspartic acid) or folic acid. 
     
     
       9. The composition of  claim 1 , wherein M is aluminum. 
     
     
       10. The composition of  claim 1 , wherein multiple copies of the bifunctional chelating agent are attached to the targeting molecule. 
     
     
       11. The composition of  claim 1 , further comprising an aqueous medium. 
     
     
       12. The composition of  claim 11 , wherein the composition is at a pH of about 3.5 to 4.5. 
     
     
       13. The composition of  claim 1 , further comprising an organic solvent. 
     
     
       14. The composition of  claim 13 , wherein the organic solvent is selected from the group consisting of acetonitrile, ethanol, dimethylformamide, methanol, acetone, propanol, isopropanol, butanol, tent-butanol, tetrahydrofuran, dioxane and dimethylsulfoxide. 
     
     
       15. The composition of  claim 11 , further comprising ascorbic acid, potassium biphthalate, ethanol and trehalose.